AU2712899A - Glp-2 derivatives with helix-content exceeding 25 percent, forming partially structured micellar-like aggregates - Google Patents

Glp-2 derivatives with helix-content exceeding 25 percent, forming partially structured micellar-like aggregates

Info

Publication number
AU2712899A
AU2712899A AU27128/99A AU2712899A AU2712899A AU 2712899 A AU2712899 A AU 2712899A AU 27128/99 A AU27128/99 A AU 27128/99A AU 2712899 A AU2712899 A AU 2712899A AU 2712899 A AU2712899 A AU 2712899A
Authority
AU
Australia
Prior art keywords
glp
helix
aggregates
percent
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU27128/99A
Other languages
English (en)
Inventor
Soren Erik Bjorn
Per Olaf Huusfeldt
Niels C. Kaarsholm
Liselotte Bjerre Knudsen
Per Franklin Nielsen
Helle Birk Olsen
Lars Thim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of AU2712899A publication Critical patent/AU2712899A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU27128/99A 1998-02-27 1999-02-25 Glp-2 derivatives with helix-content exceeding 25 percent, forming partially structured micellar-like aggregates Abandoned AU2712899A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK27198 1998-02-27
DK271/98 1998-02-27
PCT/DK1999/000080 WO1999043361A1 (fr) 1998-02-27 1999-02-25 Derives de glp-2 avec teneur en structures en helices superieure a 25 %, formant des agregats de type micellaire partiellement structures

Publications (1)

Publication Number Publication Date
AU2712899A true AU2712899A (en) 1999-09-15

Family

ID=8091669

Family Applications (1)

Application Number Title Priority Date Filing Date
AU27128/99A Abandoned AU2712899A (en) 1998-02-27 1999-02-25 Glp-2 derivatives with helix-content exceeding 25 percent, forming partially structured micellar-like aggregates

Country Status (4)

Country Link
EP (1) EP1060192A2 (fr)
JP (1) JP2002504527A (fr)
AU (1) AU2712899A (fr)
WO (1) WO1999043361A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9930882D0 (en) * 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
ES2310192T3 (es) 2000-09-18 2009-01-01 Sanos Bioscience A/S Uso de peptidos glp-2.
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
ATE396202T1 (de) * 2001-02-16 2008-06-15 Conjuchem Biotechnologies Inc Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen
WO2004035624A2 (fr) * 2002-10-14 2004-04-29 Novo Nordisk A/S Composes glp-2, leurs formulations et leurs utilisations
BRPI0408978B8 (pt) 2003-04-08 2021-07-27 Novo Nordisk As processos para regenerar uma fase estacionária cromatográfica
WO2004089985A1 (fr) 2003-04-11 2004-10-21 Novo Nordisk A/S Compositions pharmaceutiques stables
ATE541582T1 (de) 2003-06-03 2012-02-15 Novo Nordisk As Stabilisierte pharmazeutische glp-1 peptid zusammensetzungen
EP2292253A3 (fr) 2003-06-03 2011-12-14 Novo Nordisk A/S Compositions pharmaceutiques stabilisées de peptides
JP2007537981A (ja) * 2003-09-19 2007-12-27 ノボ　ノルディスク　アクティーゼルスカブ 新規の血漿タンパク質親和性タグ
CN100444898C (zh) * 2003-09-19 2008-12-24 诺沃挪第克公司 治疗肽的清蛋白结合型衍生物
RU2401276C2 (ru) * 2003-09-19 2010-10-10 Ново Нордиск А/С Производные глюкагон-подобного пептида-1 (glp-1)
KR101241862B1 (ko) * 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 신규 ｇｌｐ-1 유도체
ES2427150T3 (es) 2004-11-01 2013-10-29 Nps Pharmaceuticals, Inc. Tratamiento de pacientes con el síndrome del intestino corto con colon en continuidad
JP5755398B2 (ja) 2005-03-18 2015-07-29 ノヴォ ノルディスク アー／エス 伸長されたｇｌｐ−１化合物
WO2006097535A2 (fr) * 2005-03-18 2006-09-21 Novo Nordisk A/S Agonistes de peptides de la famille du glucagone presentant une activite similaire a la secretine
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
CN100418983C (zh) * 2005-05-11 2008-09-17 中国药科大学 人胰高血糖素相关肽-2类似物
CN102027005A (zh) 2008-05-15 2011-04-20 诺沃-诺迪斯克有限公司 通过固相合成制备的肽的纯化
KR20110039348A (ko) 2008-08-06 2011-04-15 노보 노르디스크 헬스 케어 악티엔게젤샤프트 연장된 생체내 효능을 가지는 콘쥬게이트된 단백질
JP5816097B2 (ja) 2009-01-22 2015-11-18 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
JP6086528B2 (ja) 2009-08-06 2017-03-01 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 長期のインビボ有効性を有する成長ホルモン
CN118767117A (zh) 2010-01-22 2024-10-15 诺沃—诺迪斯克保健股份有限公司 体内功效延长的生长激素
JP5980689B2 (ja) 2010-01-22 2016-08-31 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
US11045523B2 (en) 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate
WO2019086559A1 (fr) 2017-10-31 2019-05-09 Adocia Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
EP3924369A1 (fr) 2019-02-11 2021-12-22 OPKO Biologics Ltd. Analogues de glp-2 à action prolongée
EP4281039A2 (fr) 2021-01-25 2023-11-29 Mylan Ireland Limited Compositions peptidiques pharmaceutiques et leurs procédés de préparation
AU2022341538A1 (en) * 2021-09-10 2024-04-11 Zealand Pharma A/S Process for formulating compositions comprising glucagon-like-peptide-2 (glp-2) analogues

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ287945B6 (cs) * 1993-09-17 2001-03-14 Novo Nordisk A/S Inzulinový derivát a farmaceutický prostředek s jeho obsahem pro léčení diabetu
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
DE69717092T2 (de) * 1996-03-01 2003-07-24 Novo Nordisk A/S, Bagsvaerd Gebrauch einer pharmazeutischen Zusammensetzung, enthaltend ein appetitzügelndes Peptid
DE60142885D1 (de) * 1996-04-12 2010-10-07 Ontario Inc 1149336 Dem Glukagon ähnliches Peptid-2
EP0929576A1 (fr) * 1996-08-30 1999-07-21 Novo Nordisk A/S Derives de glp-2

Also Published As

Publication number Publication date
EP1060192A2 (fr) 2000-12-20
WO1999043361A1 (fr) 1999-09-02
JP2002504527A (ja) 2002-02-12
WO1999043361A8 (fr) 1999-10-14

Similar Documents

Publication Publication Date Title
AU2712899A (en) Glp-2 derivatives with helix-content exceeding 25 percent, forming partially structured micellar-like aggregates
AU2001230026A1 (en) 2,4-diaminothiazole derivatives
AU2001294606A1 (en) Substituted azepino(4,5b)indoline derivatives
PT1073647E (pt) Derivados de 12,13-ciclopropano-epotilona
AU1444800A (en) Microscale patterning and articles formed thereby
AU2001244618A1 (en) Substituted 1,3-thiazole compounds, their production and use
AU6162398A (en) Polymer nanocomposite composition
AU1271201A (en) Azepinoindole derivatives, the production and use thereof
AU4112497A (en) Glp-2 derivatives
AU6636598A (en) Novel 3,4-dialkoxyphenyl derivatives and the use thereof
AU2507801A (en) Naphthopyrans with a heterocycle in the 5,6-position, preparation, and compositions and matrices containing them
AU3501800A (en) Aqueous dispersion composition and manufacturing method for the composition
EP1469001B8 (fr) Corroles, leur dérivés chirales, et leur utilisation
AU2001294240A1 (en) 2,2-diphenylbutanamide derivatives and medicines containing the same
AU6102599A (en) Melt-mouldable composites
AU5176299A (en) Compound, composition and use
AU1979799A (en) Arylpiperazine derivatives useful as uro-selective alpha-1-adrenoceptor blockers
AU2964899A (en) 2,4-dioxo-5-arylidenimino-1,3-pyrimidines
AU2818699A (en) Spinneret
AU1513597A (en) 1,25-dihydroxy-16,22,23-trisdehydro-cholecalciferol derivatives
AU2001256791A1 (en) 5,6-trans-2-alkylvitamin d derivatives
AU1223699A (en) Aluminium acetoacetate compounds, the production and use thereof as printing inkadditives
AU2846099A (en) 1,3,4-thiadiazolylazo dyes and ink compositions containing the same
AU1791500A (en) Classifier
AU9029898A (en) 1,2,5-thiadiazolidin-3-one 1,1-dioxide derivatives

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase